Mar 05, 2018 12:18 pm UTC| Business
RADNOR, Pa., March 05, 2018 -- The law firm of Kessler Topaz Meltzer Check, LLP reminds Ubiquiti Networks, Inc. (Nasdaq:UBNT) (“Ubiquiti” or the “Company”) shareholders that a class action lawsuit has been filed in the...
Siyata Mobile to Attend US IWCE 2018
Mar 05, 2018 12:10 pm UTC| Business
MONTRAL, March 05, 2018 -- Siyata Mobile Inc. (the "Company" or "Siyata") (TSX-V:SIM) (OTCQX:SYATF) is pleased to announce that it will be attending the International Wireless Communications Expo (“IWCE”) at booth #2674...
Williams Scotsman Confirms Selected 2017 Operational Results and Provides 2018 Earnings Guidance
Mar 05, 2018 12:08 pm UTC| Business
BALTIMORE, March 05, 2018 -- WillScot Corporation (NASDAQ:WSC) (“Williams Scotsman”) today confirmed selected 2017 operational results and provided its 2018 earnings guidance. Brad Soultz, President and Chief...
Mar 05, 2018 12:07 pm UTC| Business
Naples, FL, March 05, 2018 -- World Salt Awareness Week is being celebrated this year from March 12th - 18th and is the perfect opportunity to recognize all the many benefits of salt. Salt, or sodium chloride, is...
Agios to Present at the Cowen 38th Annual Healthcare Conference Monday, March 12, 2018
Mar 05, 2018 12:02 pm UTC| Business
CAMBRIDGE, Mass., March 05, 2018 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to...
SHIRE LAUNCHES MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] IN THE U.S.
Mar 05, 2018 12:01 pm UTC| Business
SHIRE LAUNCHES MYPKFIT(TM) FOR ADVATE® [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] IN THE U.S. First and only FDA-cleared PK dosing software now available to help healthcare professionals create personalized treatment...
Artios exercises option to in-license potential first-in-class nuclease development programme
Mar 05, 2018 12:01 pm UTC| Business
Artios Pharma Ltd ("Artios" or "the Company") Artios exercises option to in-license potential first-in-class nuclease development programme Cambridge, UK, 5 March 2018. Artios Pharma, a leading DNA Damage...